{"id":40929,"date":"2021-08-01T06:37:13","date_gmt":"2021-08-01T06:37:13","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=40929"},"modified":"2021-08-01T10:17:17","modified_gmt":"2021-08-01T10:17:17","slug":"phase-1-hiv-mosaic-vaccine-study-launched-at-oxford-university","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/40929","title":{"rendered":"Phase 1 HIV mosaic vaccine study launched at Oxford university"},"content":{"rendered":"<div>\n<p class=\"HTBsubhead2articletitle\"><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><strong><span lang=\"EN-US\">On 5 July 2021, researchers at Oxford University published a press release for the launch of a phase 1 study of an HIV vaccine.<\/span><\/strong><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">The HIV-CORE 0052 study will enroll 13 HIV negative participants who are not at high risk of catching HIV.<\/span><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">It will use a mosaic vaccine called <\/span>HIVconsvX that targets different sections of the virus. The vaccines will use two doses, four weeks apart.<\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">Phase 1 studies look for whether the experimental vaccine is safe and whether it generates immune responses. This study will not produce results on whether the vaccine is effective.<\/span><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">Results are expected by April 2022.<\/span><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">The study is funded by the EU as part of the <\/span>European Aids Vaccine Initiative (EAVI2020). S<span lang=\"EN-US\">imilar studies are planned in other countries, including in Europe, Africa and the US.<\/span><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">Reference<\/span><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">Oxford University press release. HIV vaccine trial starts at Oxford. (5 July 2021).<br \/>\n<\/span><a href=\"https:\/\/www.ox.ac.uk\/news\/2021-07-05-hiv-vaccine-trial-starts-oxford\">https:\/\/www.ox.ac.uk\/news\/2021-07-05-hiv-vaccine-trial-starts-oxford<\/a><\/p>\n<\/div>\n<p><em>This article was first published on 7 July 2021.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base On 5 July 2021, researchers at Oxford University published a press release for the launch of a phase 1 study of an HIV vaccine. The HIV-CORE 0052 study will enroll 13 HIV negative participants who are &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10,42],"tags":[],"class_list":["post-40929","post","type-post","status-publish","format-standard","hentry","category-transmission-and-prevention","category-vaccines-and-microbicides"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40929","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=40929"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40929\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=40929"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=40929"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=40929"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}